How many employees does Capricor Therapeutics, Inc. have?

Capricor Therapeutics, Inc. reported 160 employees for the fiscal year ending Dec 2024, in the annual report it filed on March 26, 2025. That is up 58.4% from a year earlier.

What is Capricor Therapeutics, Inc.'s revenue per employee?

Capricor Therapeutics, Inc. brought in $22.3M of revenue in fiscal Dec 2024, which is $139K per employee. That ranks 88 of 108 companies we track in Biotechnology, where the median is $459K.

Where do these numbers come from?

Employee counts and revenue are taken from each company's own annual report (Form 10-K). Open roles are counted from the company's public job board where we have matched one. Companies report headcount once a year, sometimes rounded, so small changes can be noise.

Company data

Capricor Therapeutics, Inc. employees and revenue per employee

CAPR · Biotechnology · $450M market cap

Capricor Therapeutics, Inc. had 160 employees at the end of fiscal Dec 2024, up 58.4% from a year earlier. Revenue for the year was $22.3M, down 11.5% from a year earlier, or $139K per employee. Revenue fell while headcount grew.

Employees

160

+58.4% YoY

Revenue

$22.3M

-11.5% YoY

Revenue / employee

$139K

Peer median $459K

Rank in industry

88 of 108

Biotechnology

Headcount against revenue

Both lines start at 100 in the first year we hold, so you can see which one grew faster.

EmployeesRevenueIndexed to 100 in Dec 2016

Hover a year for the numbers.

CAPR employees and revenue by fiscal year
Year ending	Employees	Revenue	Per employee	Staff YoY	Revenue YoY
Dec 2024	160	$22.3M	$139K	+58.4%	-11.5%
Dec 2023	101	$25.2M	$249K	+36.5%	+886.8%
Dec 2022	74	$2.6M	$34K	+54.2%	+941.8%
Dec 2021	48	$244,898	$5K	+84.6%	-21.1%
Dec 2020	26	$310,250	$12K	+62.5%	-69.1%
Dec 2019	16	$1.0M	$63K	-11.1%	-39.9%
Dec 2018	18	$1.7M	$93K	-53.8%	-37.3%
Dec 2017	39	$2.7M	$68K	+2.6%	-16.4%
Dec 2016	38	$3.2M	$84K	—	—

Open roles: we have not matched a verified job board for this company yet.

Employees, last six fiscal years

Revenue per employee, last six fiscal years

Capricor Therapeutics, Inc. against similar companies

The closest industry peers by revenue, from Biotechnology.

Company	Employees	Revenue	Revenue / employee	Shape
FENC Fennec Pharmaceuticals Inc.	35	$44.6M	$1.28M	Hiring into decline
OBIO Orchestra BioMed Holdings, Inc.	86	$33.5M	$389K	Efficient growth
SEPN Septerna Inc	130	$46.0M	$353K	Efficient growth
VSTM Verastem, Inc.	102	$30.9M	$303K	Efficient growth
CBIO Crescent Biopharma, Inc.	44	$10.8M	$246K	—
KYMR Kymera Therapeutics, Inc.	238	$39.2M	$165K	Hiring into decline
CAPR Capricor Therapeutics, Inc.	160	$22.3M	$139K	Hiring into decline
ALMS Alumis Inc.	221	$24.1M	$109K	—
RLAY Relay Therapeutics, Inc.	192	$15.4M	$80K	Leaner

Every Healthcare company

Questions about Capricor Therapeutics, Inc.

How many employees does Capricor Therapeutics, Inc. have?: Capricor Therapeutics, Inc. reported 160 employees for the fiscal year ending Dec 2024, in the annual report it filed on March 26, 2025. That is up 58.4% from a year earlier.
What is Capricor Therapeutics, Inc.'s revenue per employee?: Capricor Therapeutics, Inc. brought in $22.3M of revenue in fiscal Dec 2024, which is $139K per employee. That ranks 88 of 108 companies we track in Biotechnology, where the median is $459K.
Where do these numbers come from?: Employee counts and revenue are taken from each company's own annual report (Form 10-K). Open roles are counted from the company's public job board where we have matched one. Companies report headcount once a year, sometimes rounded, so small changes can be noise.

Free game

Think you can pick better than the S&P 500?

Pick 15 stocks, lock them in, and we score them against the index every trading day for ten years. Free, with a public leaderboard.

Enter the challenge

More data

Compare CAPR with the rest of the market

See who earns the most per employee, who is hiring, and who is cutting, across every company we track.

Leaderboard Healthcare

Source: employee counts and revenue as stated in Capricor Therapeutics, Inc.'s annual reports (Form 10-K), latest filed March 26, 2025. This is data, not a recommendation to buy or sell CAPR.